Quick Answer
Rani Therapeutics Holdings, Inc. reported R&D Expense of $20.20 million for fiscal year 2025.
Rani Therapeutics Holdings, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $20.20M | -24.3% |
| 2024 | $26.68M | -32.7% |
| 2023 | $39.62M | +8.2% |
| 2022 | $36.61M | +38.2% |
| 2021 | $26.48M | +119.9% |
| 2020 | $12.04M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.22M | -47.8% | -41.5% |
| June 30, 2025 | $5.50M | -10.0% | -16.2% |
| March 31, 2025 | $6.57M | -13.4% | +6.4% |
| September 30, 2024 | $6.17M | -45.0% | +0.9% |
| June 30, 2024 | $6.12M | -44.8% | -19.4% |
| March 31, 2024 | $7.59M | -21.9% | -32.4% |
| September 30, 2023 | $11.22M | +23.3% | +1.2% |
| June 30, 2023 | $11.09M | +16.4% | +14.1% |
- Rani Therapeutics Holdings, Inc. showed a decrease of -24.3% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Rani Therapeutics Holdings, Inc.’s r&d expense has grown by 67.8% (from $12.04 million to $20.20 million).
- The most recent figure is from Rani Therapeutics Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: